Strata Skin Sciences (SSKN) Projected to Post Quarterly Earnings on Thursday

Strata Skin Sciences (NASDAQ:SSKN) is expected to be announcing its results before the market opens on Thursday, March 26th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $5.53 million for the quarter.

Strata Skin Sciences Stock Performance

NASDAQ SSKN traded down $0.04 on Wednesday, reaching $0.24. The stock had a trading volume of 723 shares, compared to its average volume of 470,328. The stock has a market cap of $1.42 million, a P/E ratio of -0.09 and a beta of 0.45. Strata Skin Sciences has a 12-month low of $0.12 and a 12-month high of $3.86. The business’s 50-day moving average price is $0.67 and its 200 day moving average price is $1.26. The company has a debt-to-equity ratio of 10.22, a quick ratio of 0.75 and a current ratio of 0.95.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Strata Skin Sciences in a report on Thursday, January 22nd. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Strata Skin Sciences stock. Susquehanna International Group LLP purchased a new position in shares of Strata Skin Sciences, Inc. (NASDAQ:SSKN) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,426 shares of the medical device company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned about 0.24% of Strata Skin Sciences at the end of the most recent reporting period. Institutional investors own 32.43% of the company’s stock.

Strata Skin Sciences Company Profile

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA?cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.